Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

Anti-PD-1 therapy yields objective clinical responses in 30–40% of advanced melanoma patients. Since most patients do not respond, predictive biomarkers to guide treatment selection are needed. We hypothesize that MHC-I/II expression is required for tumour antigen presentation and may predict anti-P...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Douglas B., Estrada, Monica V., Salgado, Roberto, Sanchez, Violeta, Doxie, Deon B., Opalenik, Susan R., Vilgelm, Anna E., Feld, Emily, Johnson, Adam S., Greenplate, Allison R., Sanders, Melinda E., Lovly, Christine M., Frederick, Dennie T., Kelley, Mark C., Richmond, Ann, Irish, Jonathan M., Shyr, Yu, Sullivan, Ryan J., Puzanov, Igor, Sosman, Jeffrey A., Balko, Justin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740184/
https://www.ncbi.nlm.nih.gov/pubmed/26822383
http://dx.doi.org/10.1038/ncomms10582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740184/
https://www.ncbi.nlm.nih.gov/pubmed/26822383
http://dx.doi.org/10.1038/ncomms10582

Ejemplares similares